stockrow
Saturday 7 November 2026
Export ODTX’s income statement to Excel — free account
Odyssey Therapeutics, Inc.
ODTX Healthcare Biotechnology
19.13
0.25
+1.32%
Follow ODTX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+3 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
6.85 | 7.91 | 10.98 | 12.49 | |
Current Ratio |
7.20 | 8.33 | 11.36 | 12.94 | |
Net Debt/EBITDA |
0.00 | 4.55 | 5.71 | 5.86 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
— | — | 0.00 | — | |
Operating CF/Net income |
— | 1.07 | 0.65 | 0.78 | |
Capex/Depreciation |
— | (0.13) | 0.09 | (0.48) | |
Interest Coverage |
— | (3,978.00) | (2,773.50) | (4,722.33) | |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.05 | 0.06 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
— | (7.26) | (1.14) | (0.87) | |
Capex per Share |
— | (0.03) | 0.00 | (0.01) | |
Free Cash Flow per Share |
— | (7.28) | (1.14) | (0.88) | |
Cash per Share |
0.00 | 31.07 | 10.26 | 6.79 | |
Shareholders Equity per Share |
0.00 | 31.80 | 13.91 | 7.83 | |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 31.80 | 13.91 | 7.83 | |
Free Cash Flow |
— | (41.18) | (34.41) | (42.02) | |
Working Capital |
164.18 | 162.89 | 293.17 | 311.70 | |
Capital Expenditures |
— | (0.15) | 0.10 | (0.48) | |
Net Current Asset Value |
136.15 | 135.90 | 258.83 | 275.47 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Assets |
— | — | 241.93 | — |
Columns are period end dates · fundamentals updated 6 Nov 2026